Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (10440)	10/30/1997 5:27:00 PM
From: Pseudo Biologist	Read Replies (2) \| Respond to of 32384

[off-topic Xoma/Seragen] Henry, Andy, Xoma used to be a hotbed for immunotoxins: antibody fragments fused to protein toxins such as ricin A chain. I think they still have some of those programs going, although, clinically at the moment, they are primarily focused on BPI and related molecules (as Andy very well knows). Seragen's molecules may be thought as similar to immunotoxins: take an anti-IL-2-receptor or anti-EGF-receptor Ab fragment and you'd get, in principle, very similar molecules, functionally, to what SRGN (or is it Lilly?) has. PB

To: Henry Niman who wrote (10440)	10/30/1997 5:31:00 PM
From: Andrew H	Respond to of 32384

The magic bullet approach sounds exciting--maybe LGND should be buying the Israeli firm. (:>) I have to agree that it must be the DAB protein. All Xomas products are BPI related, but I don't know if BPI is a fusion protein. What is really interesting here is that with LGND's brain power, they may well be looking at taking over SNRG in order to apply the magic bullet approach to a variety of cancers. Everyone knows the market for CTCL is fairly small. Maybe SNRG is a good short tem paly.